United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

20-30mmhg) below knee open toe lymphoedema garment regular size iii beige (juzo uk ltd -

United States - English - NLM (National Library of Medicine)

tianjin lantian bishui technology co,. ltd. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - antibacterial, hand wipes decreases bacteria on skin. - children under 6 years of age should be supervised when using product. stop use and ask a doctor if irritation or rash appears and lasts.

United States - English - NLM (National Library of Medicine)

tianjin lantian bishui technology co,. ltd. - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - antibacterial, hand wipes decreases bacteria on skin. - children under 6 years of age should be supervised when using product. stop use and ask a doctor if irritation or rash appears and lasts.

United States - English - NLM (National Library of Medicine)

zhuji jianhe paper co., ltd - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial decreases bacteria on skin. stop use and ask a doctor if irritation or rash appears and lasts.

United States - English - NLM (National Library of Medicine)

zhuji jianhe paper co., ltd - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antibacterial decreases bacteria on skin. stop use and ask a doctor if irritation or rash appears and lasts.

New Zealand - English - Medsafe (Medicines Safety Authority)

johnson & johnson (new zealand) limited - chlorhexidine gluconate 20%{relative} - topical solution - 20% w/v - active: chlorhexidine gluconate 20%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - sodium chloride 20%{relative} - solution for injection - 20% w/v - active: sodium chloride 20%{relative} excipient: hydrochloric acid water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; crospovidone; magnesium stearate; microcrystalline cellulose; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - rosuvastatin calcium, quantity: 20.84 mg - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; magnesium stearate; crospovidone; light magnesium oxide; titanium dioxide; lactose monohydrate; hypromellose; triacetin; brilliant blue fcf aluminium lake; iron oxide red; quinoline yellow aluminium lake - cavstat 20 should be used as an adjunct to diet when the response to diet and exercise is inadequate. ,prevention of cardiovascular events cavstat 20 is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). cavstat 20 is indicated to:,? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia cavstat 20 is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). ,prior to initiating therapy with cavstat 20, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - alprostadil 20 µg/ml - powder and solvent for solution for injection - 20 µg - alprostadil 20 µg - alprostadil